OncoHost, a Binyamina, Israel-based precision oncology company focused on advancing improved personalized cancer therapy, raised $35M in Series C funding.
The round was led by Alive Israel HealthTech VC, Leumi Partners, Menora Mivtachim, and OurCrowd. Alive’s co-founder and general managing partner, Prof. Ari Shamiss, was recently named a new member of OncoHost’s board.
The company intends to use the funds to expand its ongoing multicenter PROPHETIC trial, which utilizes PROphet®, its machine learning-based host response profiling platform, and support the imminent U.S. commercial launch of the precision oncology diagnostic solution.
Led by CEO Dr. Ofer Sharon, OncoHost combines life-science research and advanced machine learning technology to develop personalized strategies for the success of cancer therapy. Utilizing proprietary proteomic analysis, the company aims to understand patients’ unique response to therapy and overcome one of the major obstacles in clinical oncology today – resistance to therapy. Its host response profiling platform, PROphet®, analyzes proteomic changes in blood samples to monitor the dynamics of biological processes induced by the patient (i.e., the host) in response to a given cancer therapy.
The company continues to open additional clinical trial sites around the world and will be expanding its research to further cancer indications. PROphet® is set to commercial launch in the U.S. in the third quarter of 2022.